High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective
β Scribed by Susan N. Cullen; Christian Rust; Kenneth Fleming; Cathryn Edwards; Ulrich Beuers; Roger W. Chapman
- Book ID
- 116651530
- Publisher
- Elsevier Science
- Year
- 2008
- Tongue
- English
- Weight
- 174 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of highdose UDCA (28-30 mg/kg/day) ve
Ursodeoxycholic acid (UDCA) has beneficial effects in cholestatic liver diseases. In primary sclerosing cholangitis (PSC), there is evidence that high doses (Ψ20 mg/kg) of UDCA may be more effective than average doses. Biliary enrichment of UDCA at such high doses may represent the decisive factor f